<DOC>
	<DOCNO>NCT00204568</DOCNO>
	<brief_summary>The goal trial determine whether oral continuous ( metronomic ) therapy trofosfamide result similar rate progression-free time 6 month intravenous treatment adriamycin . In addition , study intend investigate level toxicity associate two treatment regimen ( safety profile ) .</brief_summary>
	<brief_title>Trofosfamide Versus Adriamycin Elderly Patients With Soft Tissue Sarcoma ( STS )</brief_title>
	<detailed_description>Group A : Adriamycin ( 60 mg/m2 , d1 , qd22 ) 75 mg/m2 may apply instead 60 mg/m2 patient 60 70 year age ( optional ) Group B : Trofosfamide ( 300 mg absolute p.o . qd 7 day , 150 mg p.o . absolute qd continuously ) In case absence toxicity treatment trofosfamide 150 mg absolute dose escalation 200 mg absolute allow ( optional )</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trofosfamide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Histologically establish metastatic ( N+ M1 = stage IV ) nonresectable soft tissue sarcoma· Grading II/III ( Guillou et al . J Clin Oncol 1997 ) At least 1 measurable tumor parameter accord RECIST criterion Evidence progression primary manifestation ( except osseous metastasis pleural effusion ) No previous radiation therapy measurable lesion No previous chemotherapy metastatic disease ; previous adjuvant chemotherapy permit progression disease within period 6 month Patients age 60 year beyond Written patient inform consent ECOG Status 02 Granulocytes &gt; = 2 x 10**9/l thrombocyte &gt; = 100 x 10**/l Serum creatinine , bilirubin &lt; 1.5 time upper limit normal value , albumin &gt; 25 g/l No severe comorbidity include psychosis previous history uncontrolled cardiovascular disease Normal leftventricular function echocardiography MUGA scan No symptomatic CNS metastases Willingness receive regular followup examination Histological grade malignancy : G I Histology gastrointestinal stromal tumor , chondrosarcoma , uterine stromal sarcoma , mesothelioma , neuroblastoma , osteosarcoma , Ewing´s sarcoma/PNET , desmoplastic round cell tumor , embryonal rhabdomyosarcoma , alveolar soft tissue sarcoma Less 5 year free secondary malignancy except adequately treat carcinoma situ ( CIS ) cervix , bladder urothelium , basal cell carcinoma , adenoma colon include pTIS , pTIN</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>